Chimeric Pneumoviridae fusion proteins as immunogens to induce cross‐neutralizing antibody responses. Issue 2 (7th December 2017)

• Record Type: Journal Article
• Authors: Olmedillas, Eduardo; Cano, Olga; Martínez, Isidoro; Luque, Daniel; Terrón, María C; McLellan, Jason S; Melero, José A; Más, Vicente
• Is Part Of: EMBO molecular medicine. Volume 10:Issue 2(2018)
• Page Start: 175
• Page End: 187
• Publication Date: 2017-12-07
• Subjects: neutralizing antibodies -- Pneumoviridae -- structure‐based design -- universal vaccines; Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.201708078
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract: Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV), two members of the Pneumoviridae family, account for the majority of severe lower respiratory tract infections worldwide in very young children. They are also a frequent cause of morbidity and mortality in the elderly and immunocompromised adults. High levels of neutralizing antibodies, mostly directed against the viral fusion (F) glycoprotein, correlate with protection against either hRSV or hMPV. However, no cross‐neutralization is observed in polyclonal antibody responses raised after virus infection or immunization with purified F proteins. Based on crystal structures of hRSV F and hMPV F, we designed chimeric F proteins in which certain residues of well‐characterized antigenic sites were swapped between the two antigens. The antigenic changes were monitored by ELISA with virus‐specific monoclonal antibodies. Inoculation of mice with these chimeras induced polyclonal cross‐neutralizing antibody responses, and mice were protected against challenge with the virus used for grafting of the heterologous antigenic site. These results provide a proof of principle for chimeric fusion proteins as single immunogens that can induce cross‐neutralizing antibody and protective responses against more than one human pneumovirus. Synopsis: Chimeric fusion (F) proteins bearing neutralizing epitopes of hRSV and hMPV offer the possibility of using a single immunogen to induce cross‐protective antibody responses against both viruses. Postfusion‐stabilized hMPV F bearing antigenic site II of hRSV induced antibodies that neutralized hRSV and hMPV and protected against an hRSV challenge. Prefusion‐stabilized hRSV F bearing antigenic site IV of hMPV also induced antibodies that cross‐neutralized hRSV and hMPV. Abstract : Chimeric fusion (F) proteins bearing neutralizing epitopes of hRSV and hMPV offer the possibility of using a single immunogen to induce cross‐protective antibody responses against both viruses.